Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

We don't have the data for that (yet). All we know is B met the primary endpoint and was the statistical equal of Daptomycin at that point. Unless someone knows something I don't, your question cannot be answered until more information is available.

A single dose regimen has been selected for phase 3 and plans are being made to move forward. We also know from an earlier PR that all 4 arms combined had a better response at 7 days in the p2b than the p2a. While I would feel more comfortable with data in hand, it may be a while before we get to see it.